Breaking News

U.K. July Retail Sales Rise 0.1%; Median Estimate 0.4% Increase
Tweet TWEET

CareFusion Loses Patent Trial Against Sigma International

CareFusion Corp. (CFN) lost a federal jury trial over claims that Sigma International General Medical Apparatus LLC infringed a patent for technology used in intravenous infusion pumps.

Jurors in San Diego today rejected CareFusion’s bid for as much as $171 million in damages over claims that its rival’s Spectrum pump infringes a U.S. patent owned by CareFusion. Sigma International denied the claims at trial.

“I did not think that we were infringing,” Roger Hungerford, president of Medina, New York-based Sigma International, said after the verdict. “We try real hard to respect all competitors’ intellectual property and if we think we might be infringing something we would design around it.”

John Allcock, an attorney for San Diego-based CareFusion, had no immediate comment and said company officials may issue a statement later.

The patent at issue relates to a force-sensor assembly for infusion pumps used in the health-care industry, according to court filings. Both companies manufacture and sell infusion pumps, which control the amount and rate of the flow of fluid and drugs administered to a patient through intravenous tubes.

U.S. District Judge Dana Sabraw presided over the trial.

CareFusion fell as much as 1 percent on news of the verdict from yesterday’s close of $24.92 in New York Stock Exchange composite trading. The stock was trading at $24.80 at 3:23 p.m. New York time.

The case is CareFusion 303 Inc. v. Sigma International, 3:10-cv-0442, U.S. District Court, Southern District of California (San Diego).

To contact the reporter on this story: Bill Callahan in federal court in San Diego at Callahan@san.rr.com

To contact the editor responsible for this story: Michael Hytha at mhytha@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.